Prognose
Analytikernes gennemsnitlige kursmål er 0,37 € (-92,24 %). Medianen er 0,37 € (-92,24 %).
| Køb |
2 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
BioSig Technologies renamed Streamex Corp after merger and gets new ticker symbol STEX
BioSig Technologies will change its name to Streamex Corp. effective September 12, 2025, following its merger with Streamex Exchange Corporation, and will change its Nasdaq ticker from BSGM to STEX; shareholders do not need to take any action and the CUSIP remains unchanged. The company completed a committed capital raise of about $15 million by selling 3,852,149 common shares at $3.90 per share and intends to use the net proceeds, among other things, to purchase gold bars and for working capital. Authorized common shares were increased from 200 million to 500 million, and through its subsidiary Streamex the company entered a three‑year exclusive partnership with Monetary Metals to tokenize yield‑bearing gold products. Apart from the rebranding, the structure and operating business are to remain unchanged. » Mere på de.investing.com
Streamex teams up with Monetary Metals for tokenized gold product with up to 4% yield
Streamex, a subsidiary of BioSig, obtained exclusive three-year rights to tokenize interest-bearing gold products from Monetary Metals and access to its leasing and bond programs. Investors could therefore earn annual returns of up to 4% on tokenized gold bar products; Streamex will finance at least 10% of the qualifying gold-leasing contracts and receive a revenue-linked share. BioSig also raised about USD 15 million through a public offering, will purchase gold bars and is using the capital increase, while InvestingPro points to weak financial metrics and short-term liquidity shortages. » Mere på de.investing.com
BioSig Technologies: shareholders approve share increase and new board structure
Shareholders of BioSig Technologies voted to increase the authorized common shares from 200 million to 500 million and approved an increase to the long-term incentive plan. They also approved measures to issue common shares and convertible debt in connection with Yorkville and the classification of the board of directors into three classes with staggered three-year terms. The vote on the issuance of about 109,070,079 common shares and one super-voting preferred share related to the Streamex acquisition was deferred pending Nasdaq approval; the meeting will resume on September 26. In addition, BioSig completed an underwritten offering of roughly $15 million and restructured convertible notes with YA II PN, Ltd. (two secured convertible notes of $25 million each, with the option to expand to $50 million). » Mere på de.investing.com
Solana gains major boost as BioSig Technologies tokenizes $1.1 billion in gold on its blockchain
BioSig Technologies will tokenize up to $1.1 billion in physical gold bullion on the Solana blockchain, significantly increasing Solana's real-world asset footprint. This move highlights Solana's technical strengths, such as low fees and high transaction speeds, and positions it as a leader in the growing asset tokenization trend. The development is seen as a strong validation of Solana's capabilities and a potential catalyst for further growth. » Mere på finance.yahoo.com
BioSig Technologies expands Streamex advisory team with Russell Starr and secures growth financing
BioSig Technologies has appointed Russell Starr as a strategic advisor for its subsidiary Streamex Exchange Corporation to advance the tokenization of gold reserves and infrastructure. The company also secured up to $1.1 billion in growth financing to support its gold-backed treasury strategy and expanded its advisory team with additional industry experts. Analysts view the stock positively due to the new strategy and potential market returns, despite the company's continued weak financial position. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde BIOSIG TECHNOLOG. DL-,001 en omsætning på 0 € og et nettoresultat på -13,28 mio. €
| (EUR) | september 2025 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | - |
| Nettoresultat | -13,28 mio. | - |
| EBITDA | -12,66 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 174,19 mio. € |
Antal aktier | 31,33 mio. |
Højeste/laveste i 52 uger | 12,86 € - 0,21 € |
| Udbytte | Nej |
Beta | 1,82 |
P/E (PE Ratio) | -0,03 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 0,42 |
P/S (PS Ratio) | 121,85 |
Virksomhedsprofil
BioSig Technologies, Inc. og dets datterselskaber driver virksomhed inden for medicinsk udstyr. Selskabets proprietære produkt omfatter et system til præcis, uafbrudt evaluering af elektrogrammer i realtid inden for elektrofysiologi (PURE EP), en signalbehandlingsplatform, der kombinerer hardware og software for at håndtere kendte udfordringer forbundet med signalindsamling og gør det muligt for elektrofysiologer at se signaler og analysere dem i realtid. Det fokuserer også på at forbedre intrakardial signalindsamling og diagnostisk information til procedurer ved atrieflimren, og er designet til at adressere langvarige begrænsninger, der bremser og forstyrrer kardiale kateterablationsprocedurer. Selskabet har en forskningsaftale med University of Minnesota om at udvikle nye terapier til behandling af sygdomme i det sympatiske nervesystem; samt et strategisk samarbejde med Mayo Foundation for Medical Education and Research om at udvikle en AI- og machine learning-softwareløsning til PURE EP-systemer. BioSig Technologies, Inc. blev stiftet i 2009 og har hovedkontor i Westport, Connecticut.
| Navn | BIOSIG TECHNOLOG. DL-,001 |
| CEO | Anthony Amato |
| Hjemsted | Los Angeles,
ct USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudstyr og -produkter |
| Børsnotering | 31.10.2014 |
| Medarbejdere | 5 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | BSGM |